Application of fetal stem cells in CKD: Does it promise renal regeneration?

Tuganbekova S., Gaipov A., Saparbayev S., Krivoruchko N., Kuzembayeva K., Shaimardanova G., Rakhimbekova G.

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction and Aims: Progression of glomerulosclerosis is inevitable in glomerular diseases and development of ESRD is relatively rapid than other causes of CKD. Application of stem cell therapy is one of the promising technology to regenerate own renal tissue, although it is very difficult due to complex tissue consisting of renal cells. Stem cells obtained from kidney tissue of fetus might be potentially effective approach to regenerate renal cells.We aimed to study efficacy of fetal renal stem cells in CKD caused by chronic glomerular diseases and determine the progression rate of CKD. Methods: This is a prospective cohort study, which included 17 patients with chronic glomerulonephritis stage 2-4 CKD, who completed three visits during the one year follow-up period. Fetal renal stem cells prepared from the kidney tissue of aborted fetus in 16-18 weeks of gestation. These stem cells cultivated in DMEM media and conserved in glycerin at - 80c. The study group received FRST via IV infusion according to study protocol every 6 months. Routine laboratory renal tests obtained during each visits. Patients were divided in to two groups according to GFR median (above and below 40 ml/min). First group included 8 patients (4 male and 4 female) and second group included 9 patients (4 male and 5 female). GFR decline rate calculated as ml/min/months. Results: All of two groups were comparable for age (39,5+/-14,8 vs 39,44+/-7,89 years), sex, disease duration and other clinical settings. Initial laboratory data and their changes after stem cell therapy are presented in Table 1. During the follow-up period, stable hemoglobin labels observed in both groups. GFR decline rate is presented in Table 2. Slow progression of renal failure observed after first injection of stem cells in first group and after second injection in second group. Conclusions: Treatment with fetal renal stem cells may be beneficial in kidney diseases caused by glomerular origin. Further studies with a large number of patients may help to achieve better results. (Table Presented).
Original languageEnglish
Title of host publicationNephrology Dialysis Transplantation
Place of PublicationS. Tuganbekova, National Scientific Medical Research Center, Internal Medicine, Astana, Kazakhstan
PublisherOxford University Press
Pagesiii157-iii158
ISBN (Print)0931-0509
Publication statusPublished - 2015

Publication series

NameNephrology Dialysis Transplantation
Volume30

Fingerprint

Fetal Stem Cells
Regeneration
Kidney
Stem Cells
Cell- and Tissue-Based Therapy
Aborted Fetus
Injections
Kidney Diseases
Glomerulonephritis
Glycerol
Chronic Kidney Failure
Renal Insufficiency
Disease Progression
Hemoglobins
Fetus
Chronic Disease
Cohort Studies
Prospective Studies

Keywords

  • *edetic acid
  • *fetal stem cell
  • *regeneration
  • chronic glomerulonephritis
  • cohort analysis
  • disease duration
  • end stage renal disease
  • female
  • fetus
  • fetus death
  • follow up
  • glomerulopathy
  • glomerulosclerosis
  • glycerol
  • hemoglobin
  • human
  • injection
  • intravenous drug administration
  • kidney cell
  • kidney disease
  • kidney failure
  • kidney parenchyma
  • laboratory
  • male
  • patient
  • pregnancy
  • stem cell
  • stem cell transplantation
  • technology
  • tissues

Cite this

S., T., A., G., S., S., N., K., K., K., G., S., & G., R. (2015). Application of fetal stem cells in CKD: Does it promise renal regeneration? In Nephrology Dialysis Transplantation (pp. iii157-iii158). (Nephrology Dialysis Transplantation; Vol. 30). S. Tuganbekova, National Scientific Medical Research Center, Internal Medicine, Astana, Kazakhstan: Oxford University Press.

Application of fetal stem cells in CKD: Does it promise renal regeneration? / S., Tuganbekova; A., Gaipov; S., Saparbayev; N., Krivoruchko; K., Kuzembayeva; G., Shaimardanova; G., Rakhimbekova.

Nephrology Dialysis Transplantation. S. Tuganbekova, National Scientific Medical Research Center, Internal Medicine, Astana, Kazakhstan : Oxford University Press, 2015. p. iii157-iii158 (Nephrology Dialysis Transplantation; Vol. 30).

Research output: Chapter in Book/Report/Conference proceedingChapter

S., T, A., G, S., S, N., K, K., K, G., S & G., R 2015, Application of fetal stem cells in CKD: Does it promise renal regeneration? in Nephrology Dialysis Transplantation. Nephrology Dialysis Transplantation, vol. 30, Oxford University Press, S. Tuganbekova, National Scientific Medical Research Center, Internal Medicine, Astana, Kazakhstan, pp. iii157-iii158.
S. T, A. G, S. S, N. K, K. K, G. S et al. Application of fetal stem cells in CKD: Does it promise renal regeneration? In Nephrology Dialysis Transplantation. S. Tuganbekova, National Scientific Medical Research Center, Internal Medicine, Astana, Kazakhstan: Oxford University Press. 2015. p. iii157-iii158. (Nephrology Dialysis Transplantation).
S., Tuganbekova ; A., Gaipov ; S., Saparbayev ; N., Krivoruchko ; K., Kuzembayeva ; G., Shaimardanova ; G., Rakhimbekova. / Application of fetal stem cells in CKD: Does it promise renal regeneration?. Nephrology Dialysis Transplantation. S. Tuganbekova, National Scientific Medical Research Center, Internal Medicine, Astana, Kazakhstan : Oxford University Press, 2015. pp. iii157-iii158 (Nephrology Dialysis Transplantation).
@inbook{0c1acc6448614582a87d54472b2285b3,
title = "Application of fetal stem cells in CKD: Does it promise renal regeneration?",
abstract = "Introduction and Aims: Progression of glomerulosclerosis is inevitable in glomerular diseases and development of ESRD is relatively rapid than other causes of CKD. Application of stem cell therapy is one of the promising technology to regenerate own renal tissue, although it is very difficult due to complex tissue consisting of renal cells. Stem cells obtained from kidney tissue of fetus might be potentially effective approach to regenerate renal cells.We aimed to study efficacy of fetal renal stem cells in CKD caused by chronic glomerular diseases and determine the progression rate of CKD. Methods: This is a prospective cohort study, which included 17 patients with chronic glomerulonephritis stage 2-4 CKD, who completed three visits during the one year follow-up period. Fetal renal stem cells prepared from the kidney tissue of aborted fetus in 16-18 weeks of gestation. These stem cells cultivated in DMEM media and conserved in glycerin at - 80c. The study group received FRST via IV infusion according to study protocol every 6 months. Routine laboratory renal tests obtained during each visits. Patients were divided in to two groups according to GFR median (above and below 40 ml/min). First group included 8 patients (4 male and 4 female) and second group included 9 patients (4 male and 5 female). GFR decline rate calculated as ml/min/months. Results: All of two groups were comparable for age (39,5+/-14,8 vs 39,44+/-7,89 years), sex, disease duration and other clinical settings. Initial laboratory data and their changes after stem cell therapy are presented in Table 1. During the follow-up period, stable hemoglobin labels observed in both groups. GFR decline rate is presented in Table 2. Slow progression of renal failure observed after first injection of stem cells in first group and after second injection in second group. Conclusions: Treatment with fetal renal stem cells may be beneficial in kidney diseases caused by glomerular origin. Further studies with a large number of patients may help to achieve better results. (Table Presented).",
keywords = "*edetic acid, *fetal stem cell, *regeneration, chronic glomerulonephritis, cohort analysis, disease duration, end stage renal disease, female, fetus, fetus death, follow up, glomerulopathy, glomerulosclerosis, glycerol, hemoglobin, human, injection, intravenous drug administration, kidney cell, kidney disease, kidney failure, kidney parenchyma, laboratory, male, patient, pregnancy, stem cell, stem cell transplantation, technology, tissues",
author = "Tuganbekova S. and Gaipov A. and Saparbayev S. and Krivoruchko N. and Kuzembayeva K. and Shaimardanova G. and Rakhimbekova G.",
year = "2015",
language = "English",
isbn = "0931-0509",
series = "Nephrology Dialysis Transplantation",
publisher = "Oxford University Press",
pages = "iii157--iii158",
booktitle = "Nephrology Dialysis Transplantation",
address = "United Kingdom",

}

TY - CHAP

T1 - Application of fetal stem cells in CKD: Does it promise renal regeneration?

AU - S., Tuganbekova

AU - A., Gaipov

AU - S., Saparbayev

AU - N., Krivoruchko

AU - K., Kuzembayeva

AU - G., Shaimardanova

AU - G., Rakhimbekova

PY - 2015

Y1 - 2015

N2 - Introduction and Aims: Progression of glomerulosclerosis is inevitable in glomerular diseases and development of ESRD is relatively rapid than other causes of CKD. Application of stem cell therapy is one of the promising technology to regenerate own renal tissue, although it is very difficult due to complex tissue consisting of renal cells. Stem cells obtained from kidney tissue of fetus might be potentially effective approach to regenerate renal cells.We aimed to study efficacy of fetal renal stem cells in CKD caused by chronic glomerular diseases and determine the progression rate of CKD. Methods: This is a prospective cohort study, which included 17 patients with chronic glomerulonephritis stage 2-4 CKD, who completed three visits during the one year follow-up period. Fetal renal stem cells prepared from the kidney tissue of aborted fetus in 16-18 weeks of gestation. These stem cells cultivated in DMEM media and conserved in glycerin at - 80c. The study group received FRST via IV infusion according to study protocol every 6 months. Routine laboratory renal tests obtained during each visits. Patients were divided in to two groups according to GFR median (above and below 40 ml/min). First group included 8 patients (4 male and 4 female) and second group included 9 patients (4 male and 5 female). GFR decline rate calculated as ml/min/months. Results: All of two groups were comparable for age (39,5+/-14,8 vs 39,44+/-7,89 years), sex, disease duration and other clinical settings. Initial laboratory data and their changes after stem cell therapy are presented in Table 1. During the follow-up period, stable hemoglobin labels observed in both groups. GFR decline rate is presented in Table 2. Slow progression of renal failure observed after first injection of stem cells in first group and after second injection in second group. Conclusions: Treatment with fetal renal stem cells may be beneficial in kidney diseases caused by glomerular origin. Further studies with a large number of patients may help to achieve better results. (Table Presented).

AB - Introduction and Aims: Progression of glomerulosclerosis is inevitable in glomerular diseases and development of ESRD is relatively rapid than other causes of CKD. Application of stem cell therapy is one of the promising technology to regenerate own renal tissue, although it is very difficult due to complex tissue consisting of renal cells. Stem cells obtained from kidney tissue of fetus might be potentially effective approach to regenerate renal cells.We aimed to study efficacy of fetal renal stem cells in CKD caused by chronic glomerular diseases and determine the progression rate of CKD. Methods: This is a prospective cohort study, which included 17 patients with chronic glomerulonephritis stage 2-4 CKD, who completed three visits during the one year follow-up period. Fetal renal stem cells prepared from the kidney tissue of aborted fetus in 16-18 weeks of gestation. These stem cells cultivated in DMEM media and conserved in glycerin at - 80c. The study group received FRST via IV infusion according to study protocol every 6 months. Routine laboratory renal tests obtained during each visits. Patients were divided in to two groups according to GFR median (above and below 40 ml/min). First group included 8 patients (4 male and 4 female) and second group included 9 patients (4 male and 5 female). GFR decline rate calculated as ml/min/months. Results: All of two groups were comparable for age (39,5+/-14,8 vs 39,44+/-7,89 years), sex, disease duration and other clinical settings. Initial laboratory data and their changes after stem cell therapy are presented in Table 1. During the follow-up period, stable hemoglobin labels observed in both groups. GFR decline rate is presented in Table 2. Slow progression of renal failure observed after first injection of stem cells in first group and after second injection in second group. Conclusions: Treatment with fetal renal stem cells may be beneficial in kidney diseases caused by glomerular origin. Further studies with a large number of patients may help to achieve better results. (Table Presented).

KW - edetic acid

KW - fetal stem cell

KW - regeneration

KW - chronic glomerulonephritis

KW - cohort analysis

KW - disease duration

KW - end stage renal disease

KW - female

KW - fetus

KW - fetus death

KW - follow up

KW - glomerulopathy

KW - glomerulosclerosis

KW - glycerol

KW - hemoglobin

KW - human

KW - injection

KW - intravenous drug administration

KW - kidney cell

KW - kidney disease

KW - kidney failure

KW - kidney parenchyma

KW - laboratory

KW - male

KW - patient

KW - pregnancy

KW - stem cell

KW - stem cell transplantation

KW - technology

KW - tissues

UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed17&NEWS=N&AN=72206690

UR - http://www.mendeley.com/research/application-fetal-stem-cells-ckd-it-promise-renal-regeneration

M3 - Chapter

SN - 0931-0509

T3 - Nephrology Dialysis Transplantation

SP - iii157-iii158

BT - Nephrology Dialysis Transplantation

PB - Oxford University Press

CY - S. Tuganbekova, National Scientific Medical Research Center, Internal Medicine, Astana, Kazakhstan

ER -